LYTIX Share Price Performance

NOK 9.04

-0.44 (-4.64%)

NOK 15.00

Fair Value

NOK 9.04

-0.44 (-4.64%)

39.7% undervalued

NOK 15.00

Fair Value

NOK 9.04

NOK 15.00

Mon, 25 May 26

Fair ValueNOK 15.00

Share Pricen/a

LYTIX Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value NOK 15 39.7% undervalued

Neoadjuvant Melanoma And Basal Cell Catalysts Will Reshape Long Term Prospects

About LYTIX

Founded: 2003
Employees: 14
CEO: Oystein Rekdal
WebsiteView website: www.lytixbiopharma.com

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of ruxotemitide for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma ASA was founded in 2003 and is based in Oslo, Norway.

Recent LYTIX News & Updates

Announcement • Apr 22

Lytix Biopharma ASA Reports Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma

Lytix Biopharma ASA announced final efficacy and safety results from its Phase II ATLAS-IT-05 study evaluating intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab in patients with advanced melanoma who have progressed following prior checkpoint inhibitor therapy. The open-label, single-arm Phase II study enrolled primarily patients with unresectable stage IIIB to IV metastatic melanoma accessible for intratumoral injection, most of whom were heavily pretreated, with 52.1% having received three or more prior lines of therapy and all having received prior immunotherapy. Treatment with ruxotemitide in combination with pembrolizumab demonstrated clinically meaningful antitumor activity and a manageable safety profile in this difficult-to-treat population. Key efficacy findings from the study include: Objective response rate (ORR): 13.6% among evaluable patients (n=22), Clinical benefit rate (CBR): 40.9%, Durable responses lasting beyond 24 months in responding patients, Median progression-free survival (PFS): 6.3 months. These outcomes highlight the potential of ruxotemitide to enhance immune responses in patients with PD-1/PD-L1 refractory melanoma, a population with limited therapeutic options. The safety profile observed in the study was consistent with the known effects of intratumoral immunotherapy and pembrolizumab. The most common treatment-related adverse events were injection-site reactions (95.7%), fatigue (30%), pruritus (26.1%), hypotension (26.1%), and anemia (21.7%). No treatment-emergent adverse events led to discontinuation of pembrolizumab. ATLAS-IT-05 is a Phase II clinical trial evaluating intratumoral ruxotemitide in combination with pembrolizumab including in patients with advanced melanoma who have progressed following prior anti-PD-1 or anti-PD-L1 therapy (NCT04796194). Patients received up to seven intratumoral injections of ruxotemitide alongside pembrolizumab administered every three weeks until disease progression or for up to 24 months. Key endpoints of the study were objective response rate per RECIST v1.1 criteria, with secondary endpoints including duration of response, progression-free survival, overall survival and safety. Ruxotemitide (LTX-315) is a first-in-class oncolytic peptide designed for intratumoral administration. The molecule disrupts tumor cells locally, leading to the release of tumor antigens and danger-associated molecular signals that may activate systemic anti-tumor immune responses. This mechanism has the potential to convert immunologically "cold" tumors into "hot" tumors and enhance responses to checkpoint inhibitor therapies.

Recent updates

No updates

Lytix Biopharma ASA Stock Price

LYTIX Share Price Performance

LYTIX Community Narratives

Neoadjuvant Melanoma And Basal Cell Catalysts Will Reshape Long Term Prospects

Neoadjuvant Melanoma And Basal Cell Catalysts Will Reshape Long Term Prospects

Trending Discussion

Recently Updated Narratives

Neoadjuvant Melanoma And Basal Cell Catalysts Will Reshape Long Term Prospects

Snowflake Analysis

Lytix Biopharma ASA Key Details

About LYTIX

Recent LYTIX News & Updates

We're Hopeful That Lytix Biopharma (OB:LYTIX) Will Use Its Cash Wisely

Neoadjuvant Melanoma And Basal Cell Catalysts Will Reshape Long Term Prospects

Lytix Biopharma ASA Reports Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma

Recent updates

Lytix Biopharma ASA Competitors

Circio Holding

Photocure

Thor Medical